连花清瘟与传统药物治疗普通肺炎和新冠病毒肺炎的疗效比较：一项荟萃分析
Efficacy of Lianhua Qingwen Compared with Conventional Drugs in the Treatment of Common Pneumonia and COVID-19 Pneumonia: A Meta-Analysis.
作者信息
Hu Caiyun, Liang Mingming, Gong Fengfeng, He Bin, Zhao Dongdong, Zhang Guoliang
机构信息
Department of Scientific Research, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, 117 Meishan Road, Hefei, Anhui, China.
Epidemiology and Health Statistics, School of Public Health, Anhui Medical University, No. 81 Meishan Road, Hefei, Anhui, China.
出版信息
Evid Based Complement Alternat Med. 2020 Sep 17;2020:5157089. doi: 10.1155/2020/5157089. eCollection 2020.
METHODS
Seven English and Chinese databases were used to search for qualified experimental studies as of July 27, 2020. All data were extracted directly from the included studies, and no special conversion formula was used. The weighted mean difference (WMD), 95% confidence interval (CI), and odds ratio (OR) were used for evaluation.
RESULTS
Forty-two studies involving 3793 subjects met the qualification criteria. For common pneumonia, a short duration of flu-like symptoms (WMD = -1.81, 95% CI = -2.12 to -1.50, < 0.001), sputum (WMD = -1.10, 95% CI = -1.50 to -0.70, < 0.001), pulmonary rale (WMD = -2.03, 95% CI = -2.74 to -1.31, < 0.001), pulmonary imaging improvement (WMD = -1.88, 95% CI = -2.28 to -1.47, < 0.001), curative effect (OR = 3.65, 95% CI = 2.81 to 4.76, < 0.001), and healing period (WMD = -1.68, 95% CI = -2.62 to -0.74, < 0.001) were associated with the Lianhua Qingwen group; subgroup analysis based on flu-like symptoms showed statistically significant improvements in fever and cough. For COVID-19 pneumonia, improvements in flu-like symptoms (OR = 3.18, 95% CI = 2.36 to 4.29, < 0.001), shortness of breath (OR = 10.62, 95% CI = 3.71 to 30.40, < 0.001), curative effect (OR = 2.49, 95% CI = 1.76 to 3.53, < 0.001), healing period (WMD = -2.06, 95% CI = -3.36 to -0.75, = 0.002), and conversion of severe cases (OR = 0.46, 95% CI = 0.27 to 0.77, = 0.003) were associated with the Lianhua Qingwen group; subgroup analysis indicated statistically significant improvements of fever, cough, fatigue, and muscle pain in the Lianhua Qingwen group compared to the conventional drug group. Regarding adverse reactions, no significant difference was detected for common pneumonia (OR = 0.75, 95% CI = 0.54 to 1.05, = 0.097).
CONCLUSIONS
Lianhua Qingwen combined with conventional drugs may be a promising therapy for treating common pneumonia and COVID-19 pneumonia.
方法
截至2020年7月27日，使用7个英文和中文数据库检索合格的实验研究。所有数据均直接从纳入研究中提取，未使用特殊的转换公式。采用加权均数差（WMD）、95%置信区间（CI）和比值比（OR）进行评估。
结果
42项涉及3793名受试者的研究符合纳入标准。对于普通肺炎，流感样症状持续时间短（WMD = -1.81，95%CI = -2.12至-1.50，<0.001）、咳痰（WMD = -1.10，95%CI = -1.50至-0.70，<0.001）、肺部啰音（WMD = -2.03，95%CI = -2.74至-1.31，<0.001）、肺部影像改善（WMD = -1.88，95%CI = -2.28至-1.47，<0.001）、疗效（OR = 3.65，95%CI = 2.81至4.76，<0.001）和治愈时间（WMD = -1.68，95%CI = -2.62至-0.74，<0.001）与连花清瘟组相关；基于流感样症状的亚组分析显示发热和咳嗽有统计学意义的改善。对于新型冠状病毒肺炎（COVID-19肺炎），流感样症状改善（OR = 3.18, 95%CI = 2.36至4.29，<0.001）、呼吸急促（OR = 10.62，95%CI = 3.71至30.40, <0.001）、疗效（OR = 2.49，95%CI = 1.76至3.53, <0.001）、治愈时间（WMD = -2.06, 95%CI = -3.36至-0.75, = 0.002）和重症转化率（OR = 0.46，95%CI = 0.27至0.77, = 0.003）与连花清瘟组相关；亚组分析表明，与传统药物组相比，连花清瘟组的发热、咳嗽、乏力和肌肉疼痛有统计学意义的改善。关于不良反应，普通肺炎未检测到显著差异（OR = 0.75，95%CI = 0.54至1.05，= 0.097）。
结论
连花清瘟联合传统药物可能是治疗普通肺炎和COVID-19肺炎的一种有前景的疗法。
Zotero 插件